Other medication classes used in diabetes

Prolonged follow-up of high-risk people treated with teplizumab to prevent progression to type 1 diabetes shows a lasting beneficial effect on beta-cell function, say researchers.

Intravitreous aflibercept and vitrectomy with panretinal laser photocoagulation appear to have similar efficacy over 24 weeks when used for the treatment of vitreous hemorrhage from proliferative diabetic retinopathy, researchers report.

People with type 2 diabetes, especially young people, do not receive treatment for hypertension and dyslipidemia in a timely manner, even when they have high cardiovascular risk, study results show.

Analysis of pretreatment follicular helper T cell subpopulations could help to identify which patients with newly diagnosed type 1 diabetes are likely to respond to abatacept immunotherapy, suggests research published in Nature Immunology.

Canadian clinicians have reported the case of a woman on long-term rosuvastatin treatment who developed rhabdomyolysis within days of starting on canagliflozin.

An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.

A major study shows that non-high-density lipoprotein levels predict atherosclerosis events over a 30-year timescale.

A large randomized trial may have settled the question of whether it is best to take blood pressure medications in the morning or evening.

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

Dasiglucagon has potential as a fast, effective treatment for severe hypoglycemia in patients with type 1 diabetes, show phase III study data presented at the 79th ADA Scientific Sessions in San Francisco, California, USA.

The potent lipid-lowering effects of the PCSK9 inhibitor evolocumab have been demonstrated in a randomized trial conducted specifically in people with type 2 diabetes.

A population-based study suggests that treatment with a statin may slow the risk for new and worsening retinopathy in patients with diabetes and dyslipidemia.

The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.

The novel, orally active vascular adhesion protein-1 inhibitor ASP8232 effectively reduces albuminuria, with few side effects, in patients with type 2 diabetes and chronic kidney disease, phase II study data show.

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

Modestly increasing glucagon levels when commencing physical activity could be an effective strategy for preventing exercise-induced hypoglycemia among patients with type 1 diabetes, results of a randomized crossover trial suggest.

Secondary analysis of the PARADIGM-HF trial shows that the adverse effects of diabetes on kidney function can be ameliorated by a neprilysin inhibitor.

The anti-cholesterol medication fenofibrate significantly reduces uric acid levels and more than halves the risk for gout in patients with type 2 diabetes, shows an analysis of the FIELD cohort.

The widespread bar on glucagon administration by basic providers of emergency medicine in the USA may prevent its use in three-quarters of cases in which it is needed, say researchers.

Intensive blood pressure management benefits patients whether or not they have diabetes and regardless of their baseline level of cardiovascular disease risk, shows a pooled analysis of the SPRINT and ACCORD-BP trials.